Navigation Links
Oral contraceptives impair muscle gains in young women
Date:4/17/2009

NEW ORLEANSMany active young women use oral contraceptives (OC) yet its effect on their body composition and exercise performance has not been thoroughly studied. A team of researchers has now examined the effects of OC on female muscle mass, and found that oral contraceptive use impairs muscle gains in young women, and is associated with lower hormone levels.

The findings are contained in a new study entitled Oral Contraceptive Use Impairs Muscle Gains in Young Women. It was conducted by Chang-Woock Lee and Steven E. Riechman, Department of Health and Kinesiology, Texas A&M University, College Station, TX; and Mark A. Newman, Human Energy Research Laboratory, University of Pittsburgh, Pittsburgh, PA. The researchers will present their findings at the 122nd Annual Meeting of the American Physiological Society (APS; www.the-aps.org/press), which is part of the Experimental Biology 2009 scientific conference. The meeting will be held April 18-22, 2009 in New Orleans.

The Study

Seventy-three generally healthy women between the ages of 18-31 were assigned to two groups and completed a 10-week whole-body resistance exercise training (RET). Group 1 consisted of 34 women who used oral contraceptives (OC). Group 2 consisted of 39 women who did not take birth control pills (non-OC). The women were encouraged to consume at least 0.5 grams of protein per pound of body weight per day (a third more than is called for by the U.S. government nutritional guidelines) to make sure they consumed enough calories and protein to promote muscle growth.

The participants exercised three times per week for ten weeks under the supervision of exercise physiologists. They performed a variety of exercises to include chest press, lat pull down, leg extension, triceps extension, arm curl and abdominal crunch. Exercise was done using standard exercise machines and each volunteer performed three sets of 6-10 repetitions per exercise at 75 percent of their maximum strength. Body composition was determined using hydrostatic weighing.

Blood samples were taken before and after the training and assessed to measure anabolic (muscle building) and catabolic (muscle breaking) hormone levels in blood. Resting and fasting blood concentrations were measured for three anabolic hormones: DHEA, DHEAS and IGF1.

Findings

The researchers found that:

  • there were significant differences in lean mass gains (OC: 2.12.1% vs. non-OC: 3.53.2% / OC: 1.01.0kg vs. no-OC: 1.61.4kg, p< 0.05). However, other muscle responses such as strength gains and arm/leg circumferences were similar between the OC and non-OC users.

  • resting/fasting blood concentrations of the anabolic hormones were significantly lower in women taking OC vs. non-OC users throughout the study period. At the same time, plasma concentrations of cortisol (catabolic hormone) were elevated.

  • those OC users had reduced DHEA hormone at the end of the training period. By contrast, the other participants' levels did not change.

Conclusion

According to the researchers, "We were surprised at the magnitude of differences in muscle gains between the two groups, with the non-OC women gaining more than 60% greater muscle mass than their OC counterpart." They added that even though the study has observed negative effects of oral contraceptive use on muscle gain in the context of resistance exercise training, "future studies are needed to help explain the reasons behind the results."


'/>"/>

Contact: Donna Krupa
dkrupa@the-aps.org
703-967-2751
American Physiological Society
Source:Eurekalert

Related biology news :

1. Texas A&M testing oral contraceptives for animals
2. Continuous oral contraceptives better at easing pain, bleeding
3. Oral contraceptives impair muscle gains in young women
4. Low oxygen in coastal waters impairs fish reproduction
5. Extended wakefulness, combined with alcohol, severely impairs driving performance
6. Breathless babies: Preemies lung function shows prolonged impairment
7. Early exposure to common weed killer impairs amphibian development
8. Telescope embedded in glasses lens promises to make driving easier for visually impaired
9. Chronic exposure to estrogen impairs some cognitive functions
10. Scientists identify cell changes leading to impaired artificial kidney function
11. Understanding how oxidative stress impairs endothelial progenitor cell function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2016)... LONDON , April 26, 2016 ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... a partnership to integrate the Onegini mobile security ... (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The ... enhanced security to access and transact across channels. ...
(Date:4/15/2016)... 15, 2016 Research and ... Biometrics Market 2016-2020,"  report to their offering.  , ... , ,The global gait biometrics market is expected ... the period 2016-2020. Gait analysis generates ... be used to compute factors that are not ...
(Date:3/31/2016)... 31, 2016  Genomics firm Nabsys has completed a ... Barrett Bready , M.D., who returned to the company ... technical leadership team, including Chief Technology Officer, John ... Steve Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... , June 27, 2016  Global demand for ... percent through 2020 to $7.2 billion.  This market ... beverages, cleaning products, biofuel production, animal feed, and ... diagnostics, and biocatalysts). Food and beverages will remain ... by increasing consumption of products containing enzymes in ...
(Date:6/27/2016)... ... 2016 , ... Newly created 4Sight Medical Solutions ... healthcare market. The company's primary focus is on new product introductions, to include ... are necessary to help companies efficiently bring their products to market. , The ...
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
Breaking Biology Technology: